QQ客服 官方微博 反馈留言

	Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders
	Goss, G.; Cobo, M.; Lu, S.; Soria, J. C.; Syrigos, K.; Lee, K. H.; Gadgeel, S. M.; Felip, E.; Goker, E.; Georgoulias, V.
刊名	EUROPEAN JOURNAL OF CANCER
	2017
卷号	72
ISSN号	0959-8049
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3539706
专题	吉林大学白求恩第一医院
推荐引用方式 GB/T 7714	Goss, G.,Cobo, M.,Lu, S.,et al. Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders[J]. EUROPEAN JOURNAL OF CANCER,2017,72.
APA	Goss, G..,Cobo, M..,Lu, S..,Soria, J. C..,Syrigos, K..,...&Ehrnrooth, E..(2017).Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders.EUROPEAN JOURNAL OF CANCER,72.
MLA	Goss, G.,et al."Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders".EUROPEAN JOURNAL OF CANCER 72(2017).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。